Abu Megurim: The 2026 Funding Test Against NIS 443 Million of Commitments

The main article already argued that 2026 is a bridge year. This follow-up isolates the funding stack itself, because that is where the easy misread sits. A reader who focuses only on the NIS 443 million of contracted 2026 payments may conclude that Abu Megurim is facing one giant payment wall. A reader who focuses only on the January 2026 equity raise may conclude that the wall is already gone. Both reads are incomplete.

To understand the 2026 test, the right lens is all-in cash flexibility, meaning how much cash is really left after the visible cash uses already on the table, not normalized NOI or AFFO. The question here is not how much the portfolio may eventually earn once it matures. The question is how many cash uses are already visible, in what order they land, and how much of the structure still depends on refinancing, fresh capital, and flexibility from the controlling shareholder side.

Three points to hold from the start

• Most of the year-end current pressure is financing-related, not operating. Out of NIS 160.2 million of current liabilities, NIS 72.3 million comes from the Rehovot loan and NIS 76.8 million from the SAFE liability. The immediate pressure point is therefore not ordinary trade payables, but two very specific financing items.
• The January 2026 raise did not create NIS 144.9 million of free dry powder. It solved one urgent layer, because the updated SAFE structure forced a share allotment and a cash payment of about NIS 40.0 million within weeks of the offering.
• The NIS 443 million figure for 2026 is real, but it is not one single balloon. These are milestone-based payments. Some obligations tied to Migdalei Assuta were pushed out, and the company itself estimates that the relevant milestones there are not expected before the third quarter of 2028. That does not remove the pressure, but it changes its nature from an immediate solvency scare into a sequencing and refinancing test.

The Pressure Map: 2026 Is a Sequencing Problem, Not Just a Size Problem

At year-end 2025 the company had NIS 51.1 million of cash and cash equivalents, negative working capital of NIS 101.3 million, and operating cash flow of NIS 9.5 million before listing costs, or slightly negative after those costs. That matters, but it is still a modest base compared with the layers of pressure already visible.

The largest number is the roughly NIS 443 million of contracted payments in 2026 and another roughly NIS 131 million in 2027 under real-estate acquisition and construction agreements. But that number alone is not enough. It does not include the Rehovot loan that now matures in June 2026 after a 90-day extension, and it does not by itself explain how the SAFE structure was cut in February 2026 into half shares and half cash.

What matters is that the company itself is not presenting a story in which existing assets fund everything. The disclosed funding logic is much more practical: existing cash, operating cash flow, additional credit secured on assets, and further debt or equity raising. That is an implicit admission that 2026 will be defined by financing choreography, not by a mature internal cash engine.

This chart is not a full arithmetic bridge of every item. It does show the proportion. The year-end cash base and the current operating cash engine are much smaller than the 2026 commitment stack, so even after the January raise the company remains dependent on refinancing and additional secured funding.

What Actually Sits Inside Current Liabilities

A superficial read of NIS 160.2 million of current liabilities may create a generalized stress signal. The breakdown says something more precise. This is not a scattered pile of suppliers and contractors. It is mostly two large stones: the Rehovot loan at NIS 72.3 million and the SAFE liability at NIS 76.8 million. Other payables and accruals were only NIS 11.2 million.

That matters because it means the immediate 2026 risk is concentrated in very concrete financing decisions. If Rehovot is refinanced and if the SAFE is resolved on the updated terms that were set after year-end, most of the year-end current pressure is already addressed. If one of those tracks stalls, the existing internal cash engine is not large enough to absorb that quietly.

That is also why the negative working-capital headline needs to be read carefully. This is not a routine operating shortfall. It is a concentrated financing issue. Management says there are no warning signs, but in practice that statement relies on three conditions that are external to the current cash engine: refinancing Rehovot, continued access to asset-backed credit, and ongoing access to debt or equity markets when needed.

The Sources: January Solved One Layer, Not the Whole Structure

The company had already disclosed on January 5, 2026 that it was examining a public equity raise, and that the controlling shareholder was considering participation, including through a setoff against merger consideration. That means the move was not a late reaction to the annual report. It was already being prepared as a funding tool.

On January 20, 2026 the company completed an offering of shares and warrants with immediate gross proceeds of about NIS 144.9 million. The disclosed use of proceeds was intentionally broad: ongoing activity, strengthening the capital and debt structure, working capital, current payments, and refinancing existing financial debt. This was not a raise earmarked for one project. It was a raise meant to support the whole structure.

What the market could miss is that this money did not arrive on top of a still-unused funding layer. The August 2025 bond expansion had raised gross proceeds of about NIS 72.5 million, but by the report date almost all of those proceeds had already been used, with only about NIS 0.4 million still remaining for Harzit 1-3. So the January raise was not built above idle debt capacity. It entered a structure that had already absorbed much of the debt layer raised only months earlier.

That tension becomes clearest in the SAFE. Under the amended investment agreement signed on January 12, 2026, if the company completed a public offering of at least NIS 50 million by the end of January, half of the investment amount would be converted into shares and the remainder would be paid in cash within 90 days. In practice, after the offering was completed, 6,013,078 shares were allotted to the investor on February 22, 2026 at NIS 6.655 per share, and on February 25, 2026 the company paid about NIS 40.0 million in cash.

That is the key point. The January raise did not only strengthen the balance sheet. It also activated an immediate cash use. Anyone counting the gross NIS 144.9 million as unrestricted fresh capacity is overstating the free liquidity that the raise actually created.

Bnei Brak and the Dividend: Where Cash Is Already Starting to Leave

The Bnei Brak deal is the clearest example of the gap between a headline transaction value and the actual funding test. In February 2026 the company signed an agreement to acquire 40 housing units in Bnei Brak. The total consideration is split into two parts: about NIS 90 million in cash and 2,055,921 shares at NIS 7.296 per share, which adds another NIS 15 million in equity consideration.

The cash leg itself has only two stages: NIS 15 million shortly after the closing conditions are met, and about NIS 75 million at the time of Form 4. At the same time, the shares are allotted to the seller against a NIS 15 million cash payment for those shares. The conservative way to read that structure is that the first stage weighs mainly through dilution and timing, while the real future cash wall sits in the roughly NIS 75 million due at Form 4.

This is not theoretical. By March 11, 2026 two of the three closing conditions were already satisfied, and only TASE approval for listing the allotted shares was still missing. By the time the annual report was approved, all conditions had already been fulfilled, the first payment had been made, and the shares had been allotted. In other words, Bnei Brak had already moved from optional pipeline to active capital use.

The dividend matters here less because of its size and more because of the signal. NIS 2.6 million does not break the company. But it is a reminder that in a REIT structure some cash is not fully optional. Even while the platform is expanding and funding remains tight, a distribution layer still exists.

Covenants and Headroom: Where There Is Cushion, and Where There Is Not

The encouraging part is that bond covenant headroom is still relatively comfortable. The trust deed requires minimum equity of NIS 125 million and an equity-to-assets ratio of at least 20%. At year-end 2025 the company stood at NIS 253.6 million of equity and a 32.5% equity-to-assets ratio.

That matters because it means the active 2026 bottleneck is not an immediate corporate covenant breach. It sits first in refinancing and collateral-based funding. The Rehovot loan itself is not presented with disclosed financial covenants, and the company states that it remains compliant with the relevant terms. But it still has to be refinanced by June 2026, and management is anchoring that assumption on one very specific argument: a 69% debt-to-value ratio and past refinancing experience.

This is the difference between accounting cushion and financing cushion. Bond covenant headroom shows that the company is not on the edge of a corporate break. It does not mean Rehovot is automatically refinanced, and it does not fund the NIS 443 million of contracted 2026 payments. So covenant headroom is a helpful condition, not a substitute for execution.

The deferred-payment structure around Migdalei Assuta sharpens the same point. On one hand it pushes part of the burden outward and prevents an overly aggressive reading of the NIS 443 million as if the whole amount lands tomorrow morning. On the other hand, the fact that the company is relying here on flexibility from the controlling-shareholder side shows that the path through 2026 still runs through capital planning, not through a mature operating cash engine that already funds itself.

Conclusion

The NIS 443 million headline is right, but the more accurate story sits in the layers beneath it. At year-end 2025 the company was facing two relatively immediate financing pressure points, Rehovot and SAFE, on top of a much larger stack of milestone-based contracted payments. The January 2026 raise improved the picture, but part of that improvement was absorbed almost immediately by the SAFE settlement.

The current thesis in one line: Abu Megurim is not being tested in 2026 on whether it owns assets, but on whether its combination of equity, refinancing, and secured borrowing can carry the visible sequence of cash uses without turning every next step into another dilution round.

The reassuring part is that bond covenant headroom is solid, that some payments were deferred, and that the SAFE path already moved forward in practice. The heavier part is that the internal cash engine at the end of 2025 was still small, the August 2025 bond proceeds were largely already consumed, and the Bnei Brak deal has already moved from idea to active commitment with a future cash wall of about NIS 75 million at Form 4.

So 2026 is not a year of testing paper asset value. It is a year of testing funding execution. If Rehovot is refinanced, if the next deals are closed without a fast return to equity issuance, and if the rental base starts carrying more weight, the read can improve quickly. If not, the market may conclude that the platform still depends too heavily on capital markets to fund its expansion pace.